For the next 5-10 years or possibly longer, a high proportion of the Cord Blood Banks (CBB)
inventory worldwide will be composed of unlicensed umbilical cord blood (UCB) units. While
Food and Drug Administration (FDA)-licensed units will be prioritized, it will always be
possible that an unlicensed unit will have known attributes, making it a better source of
cells for the given indication. Because of the wide variety of current and potential
indications as a source of cells for hematopoietic reconstitution or other form of cellular
therapy, it is critical that the investigators have access to unlicensed UCB units.